CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of diffuse large B-cell lymphoma.
  
  LEARNING OBJECTIVES

  • Apply available clinical research findings in the formulation of evidence-based therapeutic approaches for the treatment of newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
  • Appraise published Phase III clinical trial data documenting the benefit of CD79b-targeted therapy as a component of first-line treatment for patients with DLBCL, and consider the implications of these findings for current clinical management algorithms.
  • Appreciate long-term efficacy and safety data with FDA-approved chimeric antigen receptor (CAR) T-cell therapies directed at CD19, and identify patients with R/R DLBCL for whom this approach may be warranted.
  • Assess Phase III clinical trial data documenting the benefit of various CAR T-cell platforms as second-line therapy for patients with R/R DLBCL, and consider the potential application of these findings in routine clinical decision-making.
  • Review pivotal clinical trial findings leading to the FDA approval of other novel compounds with unique mechanisms of action for R/R DLBCL, and identify patients for whom treatment with these approaches would be appropriate.
  • Compare and contrast the side effects associated with available and emerging therapeutic strategies for patients with DLBCL, and formulate supportive care plans to minimize and manage these toxicities.
  • Recall ongoing clinical research evaluating novel agents and strategies for DLBCL, and counsel appropriate patients regarding the potential benefits of trial participation.

  

  ACCREDITATION STATEMENT
  In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Research To Practice. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Medical Learning Institute, Inc. (MLI) and Research to Practice (RTP) are committed to providing their participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by MLI and RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jeremy Abramson, MD
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, Century Therapeutics, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Kymera Therapeutics, Lilly, MorphoSys, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Seagen Inc.
  
  Sonali M Smith, MD
  Elwood V Jensen Professor of Medicine
  Chief, Section of Hematology/Oncology
  Co-Leader, Cancer Service Line
  Co-Director, Lymphoma Program
  The University of Chicago
  Chicago, Illinois
  
  Consulting Agreements: Adaptive Biotechnologies Corporation, ADC Therapeutics, Bantam, Bristol-Myers Squibb Company, Gamida Cell, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc; Speaking Engagement: ADC Therapeutics ICML.
  
  Jason Westin, MD, MS
  Director, Lymphoma Clinical Research
  Section Chief, Aggressive Lymphoma
  Department of Lymphoma and Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Kite, A Gilead Company, Merck, Monte Rosa Therapeutics, MorphoSys, Novartis; Contracted Research: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, MorphoSys, Novartis.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  All of the relevant financial relationships listed have been mitigated.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Genentech, a member of the Roche Group, and Kite, A Gilead Company.
  
  Release date: September 28, 2022
  Expiration date: September 30, 2023